June 4th 2025
AJ201 shows promising safety and efficacy in treating spinal and bulbar muscular atrophy, marking a potential breakthrough for patients.
Get direct access to interviews with experts, straight from the conference floor in Vienna, as well as the latest data and clinical news updates.
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
NeurologyLive® Brain Games: June 1, 2025
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.
Examining Tominersen as a Potential Treatment for Huntington Disease: The GENERATION HD2 trial
May 31st 2025The phase 2 trial tests Roche’s investigational antisense oligonucleotide therapy tominersen in patients with early stages of Huntington disease, a disease with no FDA-approved therapies available.
Pregnancy Outcomes in Ofatumumab-Treated Women Appear Consistent With General Population Rates
May 30th 2025A newly presented analysis of data from the Novartis Global Safety Database and the PRIM study assessed pregnancy and infant outcomes in women with multiple sclerosis treated with ofatumumab.
Fumarates Lead to Lower Infection-Related Healthcare Resource Utilization Relative to Anti-CD20s
A study reveals long-term fumarate therapy significantly reduces infection-related healthcare utilization in multiple sclerosis patients compared to anti-CD20 treatments.
Tracking Therapeutic Progress of Gene-Editing Agent PBGENE-DMD for Duchenne Muscular Dystrophy
Jeff Smith, PhD, chief executive officer at Precision Biosciences, explained the clinical potential and gene-editing mechanism of PBGENE-DMD, a one-time therapy targeting dystrophin mutations in Duchenne muscular dystrophy.
NeuroVoices: Elisabeth Sonesson, PhD, on Imlifidase’s Targeted, Fast-Acting Approach to GBS
The vice president and franchise lead of Autoimmune at Hansa Biopharma shed insights on imlifidase’s targeted mechanism and promising phase 2 data in treating Guillain-Barré syndrome.